Status:
COMPLETED
First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Eli Lilly and Company
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purposes of this study are to determine: The safety of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin, or docetaxel with carboplatin and any side effects that might be ...
Eligibility Criteria
Inclusion
- You must have been diagnosed with NSCLC.
- You must be able to visit the doctor's office weekly during the active treatment period and as needed during the study follow-up period.
- You must be willing and able to swallow capsules.
- Your entry labs and medical tests must meet study requirements.
- You must be willing to have blood samples drawn and tissue samples obtained for gene and protein testing.
Exclusion
- You have received radiation within 2 weeks of study enrollment.
- You have previously received any anti-cancer drug therapy for NSCLC.
- You have an active infection or other serious condition.
- You take aspirin or aspirin-like medication regularly and are not able to stop taking them for a few days during each cycle of chemotherapy.
- You have recently lost a significant amount of weight.
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
218 Patients enrolled
Trial Details
Trial ID
NCT00308750
Start Date
March 1 2006
End Date
July 1 2009
Last Update
May 13 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Burlington, North Carolina, United States, 27215
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Chapel Hill, North Carolina, United States, 27599
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Columbia, South Carolina, United States, 29210
4
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Houston, Texas, United States, 77060